Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 2 Urinary Bladder Neoplasms 1 Sarcoma 1 Ovarian Neoplasms 1 Neoplasms, Plasma Cell 1 Neoplasms 1 Esophageal Neoplasms 1 Chondrosarcoma 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1 Adenocarcinoma 1

Interventions

pembrolizumab 44 Nivolumab 29 Gemcitabine 28 Paclitaxel 19 Cisplatin 18 Ipilimumab 15 Carboplatin 14 Cyclophosphamide 13 Capecitabine 12 Dexamethasone 10 Bevacizumab 10 cemiplimab 9 Irinotecan 9 Docetaxel 9 Albumin-Bound Paclitaxel 9 130-nm albumin-bound paclitaxel 9 spartalizumab 8 Pemetrexed 8 Sorafenib 7 Rituximab 7 Cetuximab 7 fludarabine 6 Temozolomide 6 Taxes 6 Radiotherapy 6 Leucovorin 6 Fluorouracil 6 Azacitidine 6 Ascorbic Acid 6 lenvatinib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Neoplasms × resiquimod × Clear all

NCT02126579 2024-02-28

MEL60

University of Virginia

Phase 1/2 Completed

50 enrolled 13 charts

Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡